Streetbeat News

Price Targets

XPO

Raymond James analyst Patrick Tyler Brown maintains an 'Outperform' rating on XPO Logistics (NYSE:XPO) and raises the price target from $85 to $90.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 10:21 am

THC

Raymond James analyst John Ransom maintains a Strong Buy rating on Tenet Healthcare (NYSE:THC), but has lowered the price target from $95 to $90.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 10:19 am

NBIX

Raymond James analyst Danielle Brill maintains an Outperform rating on Neurocrine Biosciences (NASDAQ:NBIX) and raises the price target from $135 to $145.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 10:17 am

MPC

Raymond James analyst Justin Jenkins maintains a Strong Buy rating on Marathon Petroleum (NYSE:MPC) and raises the price target from $171 to $175.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 10:14 am

MSCI

Raymond James analyst Patrick O'Shaughnessy has maintained an 'Outperform' rating on MSCI (NYSE:MSCI) but lowered the price target from $577 to $533.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 10:12 am

HRMY

Raymond James analyst Danielle Brill maintains an 'Outperform' rating on Harmony Biosciences (NASDAQ:HRMY) and raises the price target from $26 to $27.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 10:06 am

GPN

Raymond James analyst John Davis has maintained an 'Outperform' rating on Global Payments (NYSE:GPN), but lowered the price target from $155 to $147.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 10:04 am

EPD

Raymond James analyst Justin Jenkins has maintained a 'Strong Buy' rating on Enterprise Prods Partners (NYSE:EPD), but lowered the price target from $32 to $31.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 10:02 am

TECH

Keybanc analyst Paul Knight has maintained an Overweight rating on Bio-Techne (NASDAQ:TECH) but lowered the price target from $115 to $80.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 9:52 am

RGEN

Keybanc analyst Paul Knight has maintained an Overweight rating on Repligen (NASDAQ:RGEN) but lowered the price target from $240 to $210.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 9:41 am